Skip to main content
Premium Trial:

Request an Annual Quote

France's Fluofarma and Roche Ink High-Content Assay Development Deal

NEW YORK (GenomeWeb News) – French high-content screening vendor Fluofarma said recently that it has entered into a multi-year assay development agreement with Roche.

Under the terms of the partnership, Roche and Fluofarma will work together to develop miniaturized cell-based assays using high-throughput flow cytometry and computational models to improve the predictability of hepatotoxicity and safety profiling of compounds in liver cells.

Financial terms of the partnership were not disclosed.

Fluofarma, based in Bordeaux, offers HCS services and technologies for target and drug discovery, and predictive toxicity testing. The company's HCS platform is based on automated flow cytometry, confocal imaging, and laser scanning cytometry, and enables high-throughput functional analysis of several molecular events simultaneously in living cells.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.